News

Kolltan Pharmaceuticals has raised an additional $5m to close its Series A financing at $40m. Participants in the Series A financing include Purdue Pharma, LP, HBM BioCapital LP,

Adamas Pharmaceuticals has entered into a co-operative R&D agreement (CRADA) with the US Naval Health Research Center. The deal is for preclinical studies evaluating Adamas’ triple combination antiviral

Basilea Pharmaceutica said that the US FDA has issed a warning letter to Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) related to ceftobiprole clinical trials, for the

BioNeutral Group, a specialty chemical technology-based Life Science company, has revealed the independent lab test results conducted at Microbiotest of Sterling, Virginia. The results demonstrated that Ygiene Hospital

Gecom has supplied water treatment systems that uses ADSORBSIA GTO arsenic removal media from The Dow Chemical Company. The company said that the arsenic level in over 432,000

Orexo has confirmed that Meda has initiated the launch of the drug Edluar in the US. The launch follows the US Food and Drug Administration’s approval in March

Biogaia in its interim report has reported an increase in net sales by 65% or SEK 23.8m to SEK 60.2m for the second quarter ended June 30,2009, compared

Micrus Endovascular Corporation is going to implement Pilgrim’s SmartSolve solutions through its On-Demand SaaS model. Micrus Endovascular has purchased Pilgrim’s solution for document control and employee training and

Celsion has received positive guidance for company’s Type C Chemistry Manufacturing and Controls (CMC) from FDA. The FDA has provided the company with the oral and written guidance